This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riganti, C. Articles by Bosia, A. Search for Related Content PubMed PubMed Citation Articles by Riganti, C. Articles by Bosia, A.

Nitric Oxide Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells by Inhibiting the Drug Efflux

Department of Genetics, Biology and Biochemistry, University of Torino, and Research Center on Experimental Medicine (CeRMS), Via Santena 5/bis, Turin, Italy

Requests for reprints: Dario Ghigo, Dipartimento di Genetica, Biologia eBiochimica (Sezione di Biochimica), Via Santena, 5/bis, 10126 Turin, Italy. Phone: 39-11-670-5849; Fax: 39-11-670-5845; E-mail: dario.ghigo{at}unito.it.

Multidrug resistance (MDR) is a phenomenon by which cancer cells evade the cytotoxic effects of chemotherapeutic agents. It may occur through different mechanisms, but it often correlates with the overexpression of integral membrane transporters, such as P-glycoprotein (Pgp) and MDR-associated proteins (MRPs), with resulting decrease of drug accumulation and cellular death. Doxorubicin is a substrate of Pgp; it has been suggested that its ability to induce synthesis of nitric oxide (NO) could explain, at least in part, its cytotoxic effects. Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO production (both under basal conditions and after doxorubicin stimulation). The resistance to doxorubicin could be reversed when HT29-dx cells were incubated with inducers of NO synthesis (cytokines mix, atorvastatin). Some NO donors increased the drug accumulation in HT29-dx cells in a guarosine-3':5'-cyclic monophosphate–independent way; this effect was associated with a marked reduction of doxorubicin efflux rate in HT29 and HT29-dx cells, and tyrosine nitration in the MRP3 protein. Our results suggest that onset of MDR and impairment of NO synthesis are related; this finding could point to a new strategy to reverse doxorubicin resistance in human cancer.

Key Words: doxorubicin • nitric oxide • multidrug resistance • P-glycoprotein • MDR-associated proteins

This article has been cited by other articles:

				E. Salvatorelli, P. Menna, M. Lusini, E. Covino, and G. Minotti Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 175 - 184. [Abstract] [Full Text] [PDF]

				K. KIK, M. WASOWSKA-LUKAWSKA, I. OSZCZAPOWICZ, and L. SZMIGIERO Cytotoxicity and Cellular Uptake of Doxorubicin and its Formamidine Derivatives in HL60 Sensitive and HL60/MX2 Resistant Cells Anticancer Res, April 1, 2009; 29(4): 1429 - 1433. [Abstract] [Full Text] [PDF]

				S. Doublier, C. Riganti, C. Voena, C. Costamagna, E. Aldieri, G. Pescarmona, D. Ghigo, and A. Bosia RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells Mol. Cancer Res., October 1, 2008; 6(10): 1607 - 1620. [Abstract] [Full Text] [PDF]

				C. Riganti, S. Doublier, E. Aldieri, S. Orecchia, P. G. Betta, E. Gazzano, D. Ghigo, and A. Bosia Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1{alpha} Eur. Respir. J., August 1, 2008; 32(2): 443 - 451. [Abstract] [Full Text] [PDF]

				C. Riganti, S. Doublier, C. Costamagna, E. Aldieri, G. Pescarmona, D. Ghigo, and A. Bosia Activation of Nuclear Factor-{kappa}B Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells Mol. Pharmacol., August 1, 2008; 74(2): 476 - 484. [Abstract] [Full Text] [PDF]

				P. Menna, E. Salvatorelli, and G. Minotti Doxorubicin Degradation in Cardiomyocytes J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 408 - 419. [Abstract] [Full Text] [PDF]

				O. Fantappie, M. Solazzo, N. Lasagna, F. Platini, L. Tessitore, and R. Mazzanti P-Glycoprotein Mediates Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines Cancer Res., May 15, 2007; 67(10): 4915 - 4923. [Abstract] [Full Text] [PDF]

				H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al. Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6748 - 6757. [Abstract] [Full Text] [PDF]

				A. Bratasz, N. M. Weir, N. L. Parinandi, J. L. Zweier, R. Sridhar, L. J. Ignarro, and P. Kuppusamy Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin PNAS, March 7, 2006; 103(10): 3914 - 3919. [Abstract] [Full Text] [PDF]